Changes in cholecystokinin mRNA expression in methamphetamine-induced behavioral sensitization

Neurochemistry International

Volumn 28, Issue 4, 1996, Pages 391-394

  Fukamauchi, Fumihiko ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ; COMPLEMENTARY DNA; MESSENGER RNA; METHAMPHETAMINE; NEUROPEPTIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FRONTAL CORTEX; HIPPOCAMPUS; MALE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; RAT; REINFORCEMENT; SENSITIZATION; STEREOTYPY;

EID: 0029914431     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/0197-0186(95)00104-2     Document Type: Article

References (18)

1. Borison R. L., Havdala H. S. and Diamond B. I. (1977) Chronic phenylethylamine stereotypy in rats: a new animal model for schizophrenia? Life Sci. 21, 117-122.
2. Chomczynski P. and Sacchi N. (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analyt. Biochem. 162, 156-159.
3. Crawley J. N. (1985) Comparative distribution of cholecystokinin and other neuropeptides: why is this peptide different from all other peptides? Ann. N. Y. Acad. Sci. 448, 1-8.
4. Ferrier I. N., Roberts G. W., Crow T. J., Johnstone E. C., Owens D. G. C., Lee Y. C., O'Shaughnessy D., Adrian T. E., Polak J. M. and Bloom S. R. (1983) Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia. Life Sci. 33, 475-482.
5. Fukamauchi F., Yoshikawa T., Kaneno S., Shibuya H. and Takahashi R. (1987) Dopaminergic agents affected neuronal transmission of cholecystokinin in the rat brain. Neuropeptides 10, 207-220.
6. Fuxe K., Andersson K., Locatelli V., Agnati L. F., Hökfelt T., Skirboll L. and Mutt V. (1980) Cholecystokinin peptides produce marked reduction of dopamine turnover in discrete areas in the rat brain following intraventricular injection. Eur. J. Pharmac. 67, 329-331.
7. Hökfelt T., Rehfeld J. F., Skirboll L., Ivemark B., Goldstein M. and Markey K. (1980) Evidence for coexistence of dopamine and CCK in meso-limbic neurons. Nature 285, 476-478.
8. Hurd Y. L., Lindefors N., Brodin E., Brené S., Persson H., Ungerstedt U. and Hökfelt T. (1992) Amphetamine regulation of mesolimbic dopamine/cholecystokinin neurotransmission. Brain Res. 578, 317-326.
9. Ikawa K., Watanabe A., Motohashi N. and Kaneno S. (1994) The effect of repeated administration of methamphetamine on dopamine uptake sites in rat striatum. Neurosci. Lett. 167, 37-40.
10. Ishimaru M., Hashimoto T., Obata K. and Fukamauchi F. (1995) Methamphetamine-induced dopaminergic hyperactivity is not accompanied with increase in tyrosine hydroxylase mRNA of the rat midbrain. Neurosci. Lett. 191, 107-110.
11. Kalivas P. W. and Stewart J. (1991) Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res. Rev. 16, 223-244.
12. Kuwano R., Araki K., Usui H., Fukui T., Ohtsuka E., Ikehara M. and Takahashi Y. (1984) Molecular cloning and nucleotide sequence of cDNA coding for rat brain cholecystokinin precursor. J. Biochem. 96, 923-926.
13. Matsubara K. and Matsushita A. (1985) Analysis of the long-lasting antagonistic effect of caerulein on amphetamine hyperactivity in rats. Jap. J. Pharmac. 38, 381-390.
14. Moroji T., Watanabe N., Aoki N. and Itoh S. (1982) Antipsychotic effects of ceruletide (caerulein) on chronic schizophrenia. Arch. Gen. Psychiat. 39, 485-486.
15. Snyder S. H. (1972) Catecholamines in the brain as mediators of amphetamine psychosis. Arch. Gen. Psychiat. 27, 169-179.
16. Vanderhaeghen J. J., Signeau J. C. and Gepts W. (1975) New peptides in the vertebrate CNS reacting with gastrin antibodies. Nature 257, 604-605.
17. Vanderhaeghen J. J. (1985) Neuronal cholecystokinin. In Handbook of Chemical Neuroanatomy (Bjorklund A. and Hökfelt T., eds), pp. 406-435. Elsevier, Amsterdam.
18. Yoshikawa T., Shibuya H., Kaneno S. and Toru M. (1991) Blockade of behavioral sensitization to methamphetamine by lesion of hippocampo-accumbal pathway. Life Sci. 48, 1325-1332.